Pharmafile Logo

Accession reaches milestone for digital innovation in market access

November 2022: Accession Healthcare Consulting Ltd (Accession), a specialist pharma market access consultancy and technology company, has reached a major product development milestone of its innovative digital market access product, pathwaypro®

November 2022: As pioneers in the use of digital technology in market access, Accession’s flagship digital product pathwaypro®, has this month reached its 7th year of major product development.  Completing what was set out as a 7-year plan of significant investment in R&D and NHS validation, Accession’s pathwaypro® technology including its costed pathway analysis and systems transformation methodology has undergone substantial evolution and growth.

Today, pathwaypro®, a dynamic and interactive technology platform which models a direct comparison of current patient pathways to future scenarios based on changes in the delivery of care, has been widely recognised as an innovative approach to whole system value proposition articulation and service transformation.  By allowing local health economies to understand the consequences of optimising pharmaceutical technologies into existing services, pathwaypro® creates powerful ‘invest to save’ opportunities.

Since Accession was named as “One to Watch” in the 2020 Alantra Pharma Fast 50, an annual ranking of the UK’s fastest-growing privately-owned pharma companies, the company has accelerated it’s track record and focus on using digital technology to disrupt the status quo in their sector. With use cases in multiple disease areas including dermatology, rheumatology, gastroenterology, ophthalmology, cardiology, oncology, neurology and mental health, pathwaypro® is now being used by some of the world’s largest biopharma companies.

Lindsey Rosen, Co-Founder of Accession said ‘pathwaypro® was born from Accession’s Market Access Innovators & Disruptors Movement which we launched in November 2015 and championed the need for genuine innovation in market access. We set in motion a 7-year plan of ongoing development, and here we are today, with a technology that has supported so much positive change across the NHS, and a technology that is now in perfect shape to support the NHS into 2023 and beyond with its most critical issues’.

She added ‘This is an exciting and pivotal moment for pathwaypro® and one that perfectly demonstrates why we at Accession are all so passionate about the power of market access to ensure patients gain access to life changing medicines’.

Dr John McGeagh, Director of Data Science & Digital at Accession also said: ‘Accession has invested heavily into pathwaypro® with many years of R&D to create an exceptionally successful solution for our Pharma clients to add major value to their NHS customers. Developing a unique product that supports the optimisation and transformation of local NHS services is something that all of us at Accession are incredibly proud.’

Founded in 2011, Accession delivers value, access and technology services to the global pharmaceutical industry.  As champions of innovation in market access, Accession’s proprietary digital products are transforming how their clients work, compete in the market and engage with their customers

www.accessionhealth.com

This content was provided by Accession

Documents for download:

Company Details

 Latest Content from  Accession 

Accession reaches milestone for digital innovation in market access

November 2022: Accession Healthcare Consulting Ltd (Accession), a specialist pharma market access consultancy and technology company, has reached a major product development milestone of its innovative digital market access product,...

Accession welcomes Graham Ridgway as Non-Executive Chairman

Accession, a specialist pharma market access consulting and software company, announces the appointment of accomplished software CEO Graham Ridgway as Non-Executive Chairman.

Accession announces investment to support next phase of growth

March 2021: Accession Healthcare Consulting (Accession), a specialist pharma market access consultancy, today announces that it has received private investment from a group of highly experienced healthcare and technology investors...